Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tuberculosis

Supported pathogenM. tuberculosisMycobacterium tuberculosis

Medicines already documented

Documented evidence

Registered studies whose listed conditions mention “tuberculosis”, “mycobacterium tuberculosis”, “tb”, “latent tb”.

Show all 80

Laboratory measurements against M. tuberculosis recorded in ChEMBL.

Show all 54

Other medicines to investigate

AI prediction · nothing measured

Approved medicines with AI-predicted activity ≥40% against M. tuberculosis that are not already antimicrobials, have no registered study for this condition and have no laboratory record against it. Each shows what it is already used for. They were surfaced computationally for further investigation and are not presented as established treatments for this condition.

M. tuberculosis has 870 repurposing candidates in all. 35 are already listed above, with a registered study for this condition or a laboratory record, so the other 835 are listed here.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Every repurposing candidate for M. tuberculosis, including those with documented evidence →

Registered studies

A registration describes a study; it does not establish a positive result.

When these studies started244 of 249 have a start date · most in 2023 (19)
199420102026

  • Short-course Regimens for the Treatment of Pulmonary Tuberculosis

    NCT05766267 · start 2023-11-21

    Registered record
    Registry ID
    NCT05766267
    Conditions
    Tuberculosis, Pulmonary; Tuberculosis Infection
    Interventions
    Rifabutin; Delamanid; Bedaquiline; Moxifloxacin; Pyrazinamide; Isoniazid; Rifampin; Ethambutol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Active not recruiting
    Start
    2023-11-21
    Completion
    2027-12-31
    Enrolment
    288

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Pulmonary; Tuberculosis Infection
    InterventionRifabutin; Delamanid; Bedaquiline; Moxifloxacin +4 more
    PhasePhase 2 / Phase 3
    Registry statusActive not recruiting

  • Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis

    NCT06058299 · start 2023-10-31

    Registered record
    Registry ID
    NCT06058299
    Conditions
    Pulmonary TB; Pulmonary Tuberculosis; Drug Sensitive Tuberculosis
    Interventions
    sorfequiline; Pretomanid; Linezolid; Bedaquiline; HRZE; HR
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-10-31
    Completion
    2027-02
    Enrolment
    309

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary TB; Pulmonary Tuberculosis; Drug Sensitive Tuberculosis
    Interventionsorfequiline; Pretomanid; Linezolid; Bedaquiline +2 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis

    NCT05586230 · start 2023-10-03

    Registered record
    Registry ID
    NCT05586230
    Conditions
    Tuberculosis; Rifampicin Resistant Tuberculosis
    Interventions
    Pretomanid; Optimized background regimen (OBR) for multidrug-resistant TB (MDR-TB)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-10-03
    Completion
    2026-04-28
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Rifampicin Resistant Tuberculosis
    InterventionPretomanid; Optimized background regimen (OBR) for multidrug-resistant TB (MDR-TB)
    PhasePhase 1
    Registry statusCompleted

  • A Novel Therapy With a 1-Month Ultrashort Regimen to Halt Progression From Latent Infection to Active Tuberculosis Among Close Contacts (The TB-YOUTH Study)

    NCT06022146 · start 2023-09-01

    Registered record
    Registry ID
    NCT06022146
    Conditions
    Tuberculosis; Latent Tuberculosis
    Interventions
    isoniazid and rifapentine; Rifampin and Isoniazid
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-09-01
    Completion
    2026-09-01
    Enrolment
    3,520

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Latent Tuberculosis
    Interventionisoniazid and rifapentine; Rifampin and Isoniazid
    PhasePhase 3
    Registry statusRecruiting

  • A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis

    NCT05575518 · start 2023-08-11

    Registered record
    Registry ID
    NCT05575518
    Conditions
    Tuberculosis; Human Immunodeficiency Virus
    Interventions
    Optimised rifamycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2023-08-11
    Completion
    2026-03-31
    Enrolment
    414

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Human Immunodeficiency Virus
    InterventionOptimised rifamycin
    PhasePhase 3
    Registry statusUnknown

  • A Pan-TB Regimen Targeting Host and Microbe

    NCT05686356 · start 2023-07-28

    Registered record
    Registry ID
    NCT05686356
    Conditions
    Tuberculosis
    Interventions
    Sutezolid; N-acetyl cysteine; Pretomanid; Bedaquiline; Rifafour
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Active not recruiting
    Start
    2023-07-28
    Completion
    2026-01
    Enrolment
    352

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionSutezolid; N-acetyl cysteine; Pretomanid; Bedaquiline +1 more
    PhasePhase 2 / Phase 3
    Registry statusActive not recruiting

  • Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis

    NCT05971602 · start 2023-07-26

    Registered record
    Registry ID
    NCT05971602
    Conditions
    Pulmonary Tuberculosis
    Interventions
    Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS); Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS); Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE); Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS); Isoniazid and Rifampicin (HR)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2023-07-26
    Completion
    2025-02-06
    Enrolment
    93

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis
    InterventionDelamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS); Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS); Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE); Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS) +1 more
    PhasePhase 2
    Registry statusTerminated

  • Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients

    NCT05118490 · start 2023-07-19

    Registered record
    Registry ID
    NCT05118490
    Conditions
    HIV Seropositivity; Tuberculosis; Household Contact
    Interventions
    Daily rifapentine and isoniazid for 4 weeks; Weekly rifapentine and isoniazid for 12 weeks
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2023-07-19
    Completion
    2025-12-31
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Seropositivity; Tuberculosis; Household Contact
    InterventionDaily rifapentine and isoniazid for 4 weeks; Weekly rifapentine and isoniazid for 12 weeks
    PhasePhase 4
    Registry statusActive not recruiting

  • Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin

    NCT05069688 · start 2023-07-07

    Registered record
    Registry ID
    NCT05069688
    Conditions
    Pediatric HIV Infection; Tuberculosis Infection
    Interventions
    rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2023-07-07
    Completion
    2026-12-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPediatric HIV Infection; Tuberculosis Infection
    Interventionrifampicin
    PhasePhase 1
    Registry statusRecruiting

  • Isoniazid Prophylaxis Based on Risk Factors of Tuberculosis in Living Kidney Transplantation Recipients

    NCT06512831 · start 2023-06-01

    Registered record
    Registry ID
    NCT06512831
    Conditions
    Kidney Transplantation; Tuberculosis; Isoniazid Toxicity
    Interventions
    Isoniazid
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-06-01
    Completion
    2024-03-01
    Enrolment
    1,348

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Transplantation; Tuberculosis; Isoniazid Toxicity
    InterventionIsoniazid
    PhaseNot applicable
    Registry statusCompleted

  • Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS)

    NCT05122767 · start 2023-05-24

    Registered record
    Registry ID
    NCT05122767
    Conditions
    Tuberculosis; HIV
    Interventions
    Dolutegravir; 3HP
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2023-05-24
    Completion
    2025-12-31
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; HIV
    InterventionDolutegravir; 3HP
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis

    NCT05473520 · start 2023-05-24

    Registered record
    Registry ID
    NCT05473520
    Conditions
    Tuberculosis; Acute Coronary Syndrome; Pulmonary Hypertension (Diagnosis)
    Interventions
    Doxycycline; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-05-24
    Completion
    2030-01-31
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Acute Coronary Syndrome; Pulmonary Hypertension (Diagnosis)
    InterventionDoxycycline; Placebo
    PhasePhase 3
    Registry statusRecruiting

  • Biodistribution and Pharmacokinetics of Pretomanid in Tuberculosis Patients Using 18F-Pretomanid PET

    NCT05609552 · start 2023-05-22

    Registered record
    Registry ID
    NCT05609552
    Conditions
    Tuberculosis
    Interventions
    18F-Pretomanid PET/CT
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-05-22
    Completion
    2025-10-28
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    Intervention18F-Pretomanid PET/CT
    PhaseNot recorded
    Registry statusCompleted

  • Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)

    NCT05534750 · start 2023-04-20

    Registered record
    Registry ID
    NCT05534750
    Conditions
    Tuberculosis; Multidrug Resistant Tuberculosis
    Interventions
    Tedizolid arm (SIVEXTRO®); Linezolid arm (ZYVOXID®); Standard quadruple therapy arm
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-04-20
    Completion
    2026-05
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Multidrug Resistant Tuberculosis
    InterventionTedizolid arm (SIVEXTRO®); Linezolid arm (ZYVOXID®); Standard quadruple therapy arm
    PhasePhase 2
    Registry statusRecruiting

  • PanACEA - STEP2C -01

    NCT05807399 · start 2023-04-14

    Registered record
    Registry ID
    NCT05807399
    Conditions
    Pulmonary Tuberculosis; Other Specified Pulmonary Tuberculosis
    Interventions
    BTZ-043; Rifampicin; Isoniazid; Pyrazinamide; Moxifloxacin; Alpibectir (GSK3729098); Ganfeborole (GSK3036656); Delpazolid (LCB01-0371); Pretomanid (Pa); Ethambutol (E); Ethionamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-04-14
    Completion
    2027-12-30
    Enrolment
    390

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Tuberculosis; Other Specified Pulmonary Tuberculosis
    InterventionBTZ-043; Rifampicin; Isoniazid; Pyrazinamide +7 more
    PhasePhase 2
    Registry statusRecruiting